Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 10.35
NAS:CYTK's Cash-to-Debt is ranked lower than
58% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:CYTK: 10.35 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CYTK' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.64  Med: 13.78 Max: No Debt
Current: 10.35
Equity-to-Asset 0.51
NAS:CYTK's Equity-to-Asset is ranked lower than
82% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CYTK: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CYTK' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.73  Med: 0.8 Max: 0.96
Current: 0.51
-1.73
0.96
Debt-to-Equity 0.17
NAS:CYTK's Debt-to-Equity is ranked lower than
55% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:CYTK: 0.17 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:CYTK' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.11  Med: 0.1 Max: 0.61
Current: 0.17
-0.11
0.61
Piotroski F-Score: 6
Altman Z-Score: 1.64
Beneish M-Score: -1.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -6.83
NAS:CYTK's Operating Margin % is ranked higher than
77% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:CYTK: -6.83 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CYTK' s Operating Margin % Range Over the Past 10 Years
Min: -1926.08  Med: -272.6 Max: 32
Current: -6.83
-1926.08
32
Net Margin % -14.52
NAS:CYTK's Net Margin % is ranked higher than
73% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:CYTK: -14.52 )
Ranked among companies with meaningful Net Margin % only.
NAS:CYTK' s Net Margin % Range Over the Past 10 Years
Min: -1912.57  Med: -244.9 Max: 30.1
Current: -14.52
-1912.57
30.1
ROE % -14.52
NAS:CYTK's ROE % is ranked higher than
80% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:CYTK: -14.52 )
Ranked among companies with meaningful ROE % only.
NAS:CYTK' s ROE % Range Over the Past 10 Years
Min: -85.46  Med: -50.79 Max: 32.47
Current: -14.52
-85.46
32.47
ROA % -6.93
NAS:CYTK's ROA % is ranked higher than
80% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:CYTK: -6.93 )
Ranked among companies with meaningful ROA % only.
NAS:CYTK' s ROA % Range Over the Past 10 Years
Min: -73.2  Med: -36.09 Max: 23.37
Current: -6.93
-73.2
23.37
ROC (Joel Greenblatt) % -50.15
NAS:CYTK's ROC (Joel Greenblatt) % is ranked higher than
93% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:CYTK: -50.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CYTK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3507.33  Med: -583.53 Max: 710.88
Current: -50.15
-3507.33
710.88
3-Year Revenue Growth Rate 30.50
NAS:CYTK's 3-Year Revenue Growth Rate is ranked higher than
81% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:CYTK: 30.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CYTK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.1 Max: 154.5
Current: 30.5
0
154.5
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CYTK's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CYTK Guru Trades in Q3 2016

Paul Tudor Jones 41,300 sh (+150.76%)
» More
Q4 2016

CYTK Guru Trades in Q4 2016

Paul Tudor Jones 17,240 sh (-58.26%)
» More
Q1 2017

CYTK Guru Trades in Q1 2017

Joel Greenblatt 49,907 sh (New)
Paul Tudor Jones 26,166 sh (+51.77%)
» More
Q2 2017

CYTK Guru Trades in Q2 2017

Louis Moore Bacon 50,000 sh (New)
Paul Tudor Jones Sold Out
Joel Greenblatt 16,860 sh (-66.22%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Reduce -66.22%0.01%$11.2 - $17 $ 14.101%16,860
Joel Greenblatt 2017-03-31 New Buy0.01%$10.05 - $13.65 $ 14.1021%49,907
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RVNC, NAS:IMGN, NAS:GTHX, NAS:PTCT, NAS:RETA, NAS:AKBA, NAS:ANIK, NAS:NTLA, NAS:LJPC, NAS:AKAO, NAS:AMAG, NAS:VNDA, NAS:ABEO, NAS:TGTX, NAS:BOLD, NAS:ALDR, NAS:ACRS, NAS:PRTK, NAS:ADRO, NAS:DOVA » details
Traded in other countries:KK3A.Germany,
Headquarter Location:USA
Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Cytokinetics is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

Ratios

vs
industry
vs
history
PB Ratio 3.67
CYTK's PB Ratio is ranked lower than
63% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CYTK: 3.67 )
Ranked among companies with meaningful PB Ratio only.
CYTK' s PB Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.37 Max: 9.96
Current: 3.67
0.89
9.96
PS Ratio 6.19
CYTK's PS Ratio is ranked higher than
70% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CYTK: 6.19 )
Ranked among companies with meaningful PS Ratio only.
CYTK' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 11.07 Max: 96.23
Current: 6.19
1.84
96.23
Price-to-Free-Cash-Flow 48.95
CYTK's Price-to-Free-Cash-Flow is ranked higher than
66% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. CYTK: 48.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CYTK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.69  Med: 42.9 Max: 98.53
Current: 48.95
13.69
98.53
Price-to-Operating-Cash-Flow 39.78
CYTK's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. CYTK: 39.78 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CYTK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.01  Med: 37.47 Max: 87.92
Current: 39.78
13.01
87.92
EV-to-EBIT -88.09
CYTK's EV-to-EBIT is ranked lower than
78% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CYTK: -88.09 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTK' s EV-to-EBIT Range Over the Past 10 Years
Min: -91.34  Med: -1.7 Max: 210.9
Current: -88.09
-91.34
210.9
EV-to-EBITDA -114.59
CYTK's EV-to-EBITDA is ranked lower than
78% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CYTK: -114.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -118.82  Med: -1.8 Max: 163.8
Current: -114.59
-118.82
163.8
EV-to-Revenue 4.84
CYTK's EV-to-Revenue is ranked higher than
79% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CYTK: 4.84 )
Ranked among companies with meaningful EV-to-Revenue only.
CYTK' s EV-to-Revenue Range Over the Past 10 Years
Min: -7.1  Med: 5.8 Max: 85
Current: 4.84
-7.1
85
Current Ratio 10.21
CYTK's Current Ratio is ranked higher than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CYTK: 10.21 )
Ranked among companies with meaningful Current Ratio only.
CYTK' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 6.11 Max: 23.3
Current: 10.21
1.85
23.3
Quick Ratio 10.21
CYTK's Quick Ratio is ranked higher than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CYTK: 10.21 )
Ranked among companies with meaningful Quick Ratio only.
CYTK' s Quick Ratio Range Over the Past 10 Years
Min: 1.85  Med: 6.11 Max: 23.3
Current: 10.21
1.85
23.3
Days Sales Outstanding 3.34
CYTK's Days Sales Outstanding is ranked higher than
95% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CYTK: 3.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.06  Med: 1.05 Max: 362.71
Current: 3.34
0.06
362.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.80
CYTK's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CYTK: -9.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -182.7  Med: -22.85 Max: -9.8
Current: -9.8
-182.7
-9.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.38
CYTK's Price-to-Net-Cash is ranked lower than
71% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CYTK: 4.38 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CYTK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.99  Med: 3.33 Max: 102
Current: 4.38
0.99
102
Price-to-Net-Current-Asset-Value 4.24
CYTK's Price-to-Net-Current-Asset-Value is ranked lower than
70% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CYTK: 4.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CYTK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.96  Med: 3.19 Max: 13.53
Current: 4.24
0.96
13.53
Price-to-Tangible-Book 3.66
CYTK's Price-to-Tangible-Book is ranked lower than
53% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CYTK: 3.66 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYTK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.95  Med: 2.64 Max: 7.73
Current: 3.66
0.95
7.73
Price-to-Median-PS-Value 0.56
CYTK's Price-to-Median-PS-Value is ranked higher than
81% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CYTK: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.08 Max: 7.7
Current: 0.56
0.18
7.7
Earnings Yield (Greenblatt) % -1.14
CYTK's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CYTK: -1.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -907.7  Med: -32.15 Max: 239.1
Current: -1.14
-907.7
239.1

More Statistics

Revenue (TTM) (Mil) $99.39
EPS (TTM) $ -0.28
Beta2.10
Short Percentage of Float9.68%
52-Week Range $8.51 - 17.20
Shares Outstanding (Mil)53.67

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 22 40 70 121
EPS ($) -2.30 -1.97 -1.80 -1.29
EPS without NRI ($) -2.30 -1.97 -1.80 -1.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTK

Headlines

Articles On GuruFocus.com
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Sc Sep 11 2017 
Cytokinetics to Present at September Investor Conferences Sep 05 2017 
Cytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanes Aug 02 2017 
Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients W Jul 27 2017 
Cytokinetics to Announce Second Quarter Results on August 2, 2017 Jul 26 2017 
Cytokinetics to Participate in Panel on Neuromuscular Disorders at the JMP Securities Life Sciences Jun 13 2017 
Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular A May 15 2017 
Cytokinetics to Hold Annual Meeting of Stockholders May 11 2017 
Cytokinetics Announces Pricing of Public Offering of Common Stock May 08 2017 
Cytokinetics Announces Proposed Public Offering of Common Stock May 08 2017 

More From Other Websites
Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of... Sep 19 2017
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual... Sep 18 2017
Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock Sep 15 2017
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual... Sep 11 2017
ETFs with exposure to Cytokinetics, Inc. : September 7, 2017 Sep 07 2017
Cytokinetics to Present at September Investor Conferences Sep 05 2017
Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : August 29,... Aug 29 2017
ETFs with exposure to Cytokinetics, Inc. : August 21, 2017 Aug 21 2017
Edited Transcript of CYTK earnings conference call or presentation 2-Aug-17 8:30pm GMT Aug 12 2017
Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 Aug 10 2017
Cytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : August 4, 2017 Aug 04 2017
Featured Company News - Cytokinetics Announces Positive Results for Phase-2 Clinical Trial of... Aug 04 2017
Cytokinetics reports 2Q loss Aug 02 2017
Cytokinetics, Inc. Reports Second Quarter 2017 Financial Results Aug 02 2017
Investor Network: Cytokinetics, Incorporated to Host Earnings Call Aug 02 2017
Cytokinetics Announces Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in... Aug 02 2017
Cytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : July 31, 2017 Jul 31 2017
Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients... Jul 27 2017
Cytokinetics to Announce Second Quarter Results on August 2, 2017 Jul 26 2017
Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : July 17, 2017 Jul 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}